Mar, 22 2024
In 2015, the FDA approved Flibanserin (Addyi) for treating female sexual interest/arousal disorder (FSIAD) in premenopausal women. This guide delves into how Addyi, described as 'female Viagra', works, its benefits, side effects, and the need for more inclusive research. Bremelanotide (Vyleesi), another FSIAD medication, is also discussed alongside the off-label use of Viagra in women.